checkAd

     221  0 Kommentare PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX (racemic ketamine) in the U.S. - Seite 3

    This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction. 



    globenewswire
    0 Follower
    Autor folgen
    Seite 3 von 3

    Verfasst von globenewswire
    PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX (racemic ketamine) in the U.S. - Seite 3 Expected FDA approval for KETARX (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024TORONTO, June 20, 2023 (GLOBE NEWSWIRE) - PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a …